Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study.

被引：7

作者：

Al-Batran, Salah-Eddin

Shitara, Kohei

Folprecht, Gunnar

Moehler, Markus H.

Goekkurt, Eray

Ben-Aharon, Irit

Lonardi, Sara

Stein, Stacey

Hubert, Ayala

Chau, Ian

Mishaeli, Moshe

Villanueva, Luis

Kavan, Petr

Fang, Xiao

Shih, Chie-Schin

Bhagia, Pooja

Wyrwicz, Lucjan S.

机构：

[1] UCT Univ Canc Ctr, Krankenhaus Nordwest, Frankfurt, Germany

[2] Frankfurter Inst Klin Krebsforsch IKF GmbH, Krankenhaus Nordwest, Frankfurt, Germany

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[4] Univ Hosp Carl Gustav Carus, Dresden, Germany

[5] Tech Univ Dresden, Dresden, Germany

[6] Johannes Gutenberg Univ Clin, Dept Med, Mainz, Germany

[7] Johannes Gutenberg Univ Clin, Res Ctr Immunotherapy, Mainz, Germany

[8] Practice Hematol & Oncol HOPE, Hamburg, Germany

[9] Rambam Hlth Care Ctr, Div Oncol, Haifa, Israel

[10] Veneto Inst Oncol IOV IRCCS, Padua, Italy

[11] Yale Canc Ctr, New Haven, CT USA

[12] Hadassah Hebrew Med Ctr, Sharett Inst Oncol, Jerusalem, Israel

[13] Royal Marsden NHS Fdn Trust, London, England

[14] Meir Med Ctr, Oncol Dept, Kefar Sava, Israel

[15] Fdn Arturo Lopez Perez FALP, Santiago, Chile

[16] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ, Canada

[17] Merck & Co Inc, Rahway, NJ 07065 USA

[18] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

281-318-430; 281-270-151-2679; 613-4678-146; 613-135-244-3829; 281-318-5770; 261-566-148-2649; 298-145-222-2710; 3; 2; 242; 2861; 239; 193; 54; 256; 16; 8; 1;

D O I：

10.1200/JCO.2024.42.3_suppl.247

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：247 / 247

页数：1